Advertisement

National Heart, Lung, and Blood Institute Selects Moffitt Cancer Center as One of Five Cell Therapies Processing Facilities


Moffitt Cancer Center has been selected as a Cell Therapies Processing Facility by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

Moffitt is one of five institutions that make up the NHLBI’s Production Assistance for Cellular Therapies group. The four other institutions that make up the Production Assistance for Cellular Therapies group include City of Hope, University of Miami, University of Minnesota, and Baylor College of Medicine.

This exclusive group includes the only ­NHLBI-approved facilities to produce cell-based therapies for scientific research. As part of the NHLBI Production Assistance for Cellular Therapies group, Moffitt will manufacture human cells that will be used to help develop early-stage clinical trials to evaluate the safety and effectiveness of new therapies.

Linda L. Kelley, PhD

Linda L. Kelley, PhD

“Being selected as one of the ­NHLBI’s [Production Assistance for Cellular Therapies] facilities recognizes Moffitt as a leader in cancer research and treatment. Cell therapy production is an extremely specialized area. There are strict requirements and regulations through the U.S. Food and Drug Administration that must be met,” said Linda L. Kelley, PhD, principal investigator and Director of Moffitt’s Cell Therapy Facility. “Our scientists look forward to assisting the NHLBI and its partners with bridging the gap between basic and clinical research and generating possible new therapies for patients.”

Program Goal

The goal of the Production Assistance for Cellular Therapies program is to advance cellular therapy research in the areas of organs, biologic systems, and damaged and diseased tissue regeneration, in addition to creating targeted treatments for serious diseases without effective therapies. The cell-processing facilities are charged with implementing the rapid, safe, and consistent transition of innovative treatment concepts to clinical practice, as well as supplying clinical-grade products produced in a manner that is compliant with applicable regulatory requirements.

The NHLBI provides each Production Assistance for Cellular Therapies group member with infrastructure funding. There is also the opportunity to receive additional funds as members receive and complete cell-based therapy requests from institutions across the country. ■



Advertisement

Advertisement



Advertisement

click me